CXCR2 and neutropenia: However, despite these encouraging findings, there remains a gap in understanding whether CXCR4 antagonists can effectively address peripheral blood neutropenia, abnormal BM neutrophil counts, and infection susceptibility specifically in patients harboring CXCR2 LOF variants.